Priser
Platform
Blog
Om os
Download
Cloudia Research
Cloudia Research
Borsa Italiana
0

Om

Cloudia Research S.p.A. is a specialized company focused on biotechnology research and development, particularly within the medical and healthcare sectors. Its primary purpose is to advance scientific knowledge and create innovative solutions for pressing medical challenges, targeting diseases that require novel therapeutic approaches. The company is known for leveraging cloud-based technologies to enhance data analysis and streamline collaborative research efforts, making it a leader in using digital tools to accelerate biotechnological advancements. As such, Cloudia Research impacts industries including pharmaceuticals, diagnostics, and medical device manufacturing. By integrating cutting-edge technology with biological research, the company plays a significant role in advancing personalized medicine and improving patient outcomes. With a commitment to scientific rigor and innovation, Cloudia Research S.p.A. contributes to the broader life sciences market, pushing the boundaries of what is possible in healthcare and treatment solutions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CLOUDIA RESEARCH MED ENDAVU: Køb Cloudia Research ($AGAIN) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Cloudia Research, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

TickerAGAIN
Land
Italien
Antal medarbejdere114
Hjemmesidecloudiaresearch.com
SektorTeknologi
IndustriInformationsteknologitjenester

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
0%100%0%0%0%